1. Scrip
  2. >>R&D
  3. >>Clinical Trials

SOTIO's Dendritic Cell Vaccines Have Promise In Ovary And Lung Cancer

 
• By John Davis

Interim Phase II data has shown that SOTIO's dendritic cell-based cancer vaccine candidates have efficacy in patients with ovarian cancer and non-small cell lung cancer.

Plant
New cancer vaccines may be on the horizon • Source: Shutterstock

Cancer vaccine research has had its fair share of disappointing clinical trial results, but a central European company, Sotio AS, owned by the international finance group, PPF Group, presented positive Phase II results with two DCVAC vaccines, for potential use in ovarian and lung cancer, at the ASCO meeting on June 3, backing the promise of this emerging therapeutic category.

The use of DCVAC/OvCa in patients with ovarian cancer, and DCVAC/LuCa in patients with lung cancer, significantly decreased the risk...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D